Baysa Anton, Sagave Julia, Carpi Andrea, Zaglia Tania, Campesan Marika, Dahl Christen P, Bilbija Dusan, Troitskaya Maria, Gullestad Lars, Giorgio Marco, Mongillo Marco, Di Lisa Fabio, Vaage Jarle I, Valen Guro
Division of Physiology, Department of Molecular Medicine, Institute of Basic Medical Science, University of Oslo, Postbox 1103, Blindern, 0317, Oslo, Norway,
Basic Res Cardiol. 2015 Mar;110(2):13. doi: 10.1007/s00395-015-0470-0. Epub 2015 Feb 14.
Heart rupture and heart failure are deleterious complications of myocardial infarction. The ShcA gene encodes for three protein isoforms, p46-, p52- and p66ShcA. p66ShcA induces oxidative stress. We studied the role of p66ShcA post-infarction. Expression of p66ShcA was analyzed in myocardium of patients with stable angina (n = 11), in explanted hearts with end-stage ischemic heart failure (n = 9) and compared to non-failing hearts not suitable for donation (n = 7). p66ShcA was increased in the patients with stable angina, but not in the patients with end-stage heart failure. Mice (n = 105) were subjected to coronary artery ligation. p66ShcA expression and phosphorylation were evaluated over a 6-week period. p66ShcA expression increased transiently during the first weeks post-infarction. p66ShcA knockout mice (KO) were compared to wild type (n = 82 in total). KO had improved survival and reduced occurrence of heart rupture post-infarction. Expression of cardiac matrix metalloproteinase 2 (MMP-2) was reduced; fibroblast activation and collagen accumulation were facilitated, while oxidative stress was attenuated in KO early post-infarction. 6 weeks post-infarction, reactive fibrosis and left ventricular dilatation were diminished in KO. p66ShcA regulation of MMP-2 was demonstrated in cultured fibroblasts: lack or overexpression of p66ShcA in vitro altered expression of MMP-2. Myocardial infarction induced cardiac p66ShcA. Deletion of p66ShcA improved early survival, myocardial healing and reduced cardiac fibrosis. Upon myocardial infarction p66ShcA regulates MMP-2 activation. The role of p66ShcA in human cardiac disease deserves further study as a potential target for reducing adverse cardiac remodeling post-infarction.
心脏破裂和心力衰竭是心肌梗死的有害并发症。ShcA基因编码三种蛋白质异构体,即p46-、p52-和p66ShcA。p66ShcA可诱导氧化应激。我们研究了p66ShcA在心肌梗死后的作用。分析了稳定型心绞痛患者(n = 11)、终末期缺血性心力衰竭患者的离体心脏(n = 9)心肌中p66ShcA的表达,并与不适合捐赠的非衰竭心脏(n = 7)进行比较。稳定型心绞痛患者的p66ShcA增加,但终末期心力衰竭患者未增加。对105只小鼠进行冠状动脉结扎。在6周内评估p66ShcA的表达和磷酸化。p66ShcA的表达在心肌梗死后的最初几周内短暂增加。将p66ShcA基因敲除小鼠(KO)与野生型小鼠(共82只)进行比较。基因敲除小鼠的生存率提高,心肌梗死后心脏破裂的发生率降低。心脏基质金属蛋白酶2(MMP-2)的表达降低;促进了成纤维细胞活化和胶原蛋白积累,而基因敲除小鼠在心肌梗死后早期氧化应激减弱。心肌梗死后6周,基因敲除小鼠的反应性纤维化和左心室扩张减轻。在培养的成纤维细胞中证实了p66ShcA对MMP-2的调节:体外p66ShcA的缺失或过表达改变了MMP-2的表达。心肌梗死诱导心脏p66ShcA。p66ShcA的缺失改善了早期生存率、心肌愈合并减少了心脏纤维化。心肌梗死后,p66ShcA调节MMP-2的激活。p66ShcA在人类心脏病中的作用作为减少心肌梗死后不良心脏重塑的潜在靶点值得进一步研究。